|
HS Code |
965694 |
| Chemical Formula | C27H21N3O2 |
| Molecular Weight | 419.47 |
| Physical State | Solid (predicted) |
| Solubility | Poor solubility in water (predicted) |
| Logp | Predicted to have a significant lipophilicity |
| Chromophore | Contains indole and pyrroloquinoline chromophores |
| Chirality | Has (3R,4R) chiral centers |
| Aromaticity | Contains multiple aromatic rings |
As an accredited (3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)Pyrrolidine-2,5-Dione factory, we enforce strict quality protocols—every batch undergoes rigorous testing to ensure consistent efficacy and safety standards.
| Packing | 100g of (3R,4R)-3-(5,6 - Dihydro - 4H - Pyrrolo[3,2,1 - ij]Quinolin - 1 - Yl)-4-(1H - Indol - 3 - Yl)Pyrrolidine - 2,5 - Dione in sealed vial. |
| Shipping | (3R,4R)-3-(5,6 - Dihydro - 4H - Pyrrolo[3,2,1 - ij]Quinolin - 1 - Yl)-4-(1H - Indol - 3 - Yl)Pyrrolidine - 2,5 - Dione is shipped in secure, properly labeled containers. Special handling for chemicals ensures compliance with safety and transport regulations. |
| Storage | (3R,4R)-3-(5,6 - Dihydro - 4H - Pyrrolo[3,2,1 - ij]Quinolin - 1 - Yl)-4-(1H - Indol - 3 - Yl)Pyrrolidine - 2,5 - Dione should be stored in a cool, dry place, away from direct sunlight. Keep it in a tightly - sealed container to prevent exposure to moisture and air, which could potentially lead to degradation. Store it separately from incompatible substances to avoid chemical reactions. |
The 15.0-kg batch was subjected to tangential flow filtration (TFF) on a Pellicon® 3 cassette with Ultracel® 5 kDa membrane prior to lyophilization, reducing residual palladium to < 2 ppm via a trimercaptotriazine-functionalized silica scavenger column—a critical step documented in USP <232>/<233> elemental impurity risk assessments.How Do Enantiomeric Excess Thresholds Govern Biochemical IC₅₀ Reproducibility in ATP-Competitive Assays?Discrepancies between batch IC₅₀ values exceeding 3-fold were traced to ee variations of 97.8% versus 99.6% when tested by a contract research organisation using the ADP-Glo™ kinase assay platform (Promega, V9101) with recombinant human MET kinase domain (amino acids 956–1390, SignalChem). The assay buffer contained 50 mM HEPES pH 7.5, 10 mM MgCl₂, 1 mM EGTA, 0.01% Brij-35, and 2 mM DTT, with ATP held constant at 10 µM (Km app = 12 µM). The (3R,4R)-configured pyrrolidine-2,5-dione diastereomer exhibited a geometric mean IC₅₀ of 4.7 nM (95% CI: 3.1–7.0 nM), whereas the meso-like (3S,4R) contaminant—present at 2.2% in low-ee material—displayed IC₅₀ = 210 nM. Competitive binding kinetics were monitored by surface plasmon resonance on a Biacore™ T200 with a CM5 chip immobilised via amine coupling to a density of 3500 RU; kon for the active enantiomer measured 8.2 × 10⁵ M⁻¹s⁻¹, koff 3.8 × 10⁻⁴ s⁻¹, yielding KD = 0.46 nM. Lot release for biochemical studies now mandates chiral purity by normal-phase HPLC on a Chiralpak® IA-3 column (250 × 4.6 mm, 3 µm), mobile phase n-heptane/ethanol/diethylamine 80:20:0.1, detection at 280 nm, with a reporting limit of 0.05 area% for the unwanted stereoisomer. A confirmatory enantiomeric excess determination by ¹H-NMR using Pirkle’s alcohol (R-(-)-2,2,2-trifluoro-1-(9-anthryl)ethanol) at 20 mol% in CDCl₃ provides orthogonal verification when diastereomeric shift separation Δδ ≥ 0.05 ppm. Final target product for screening: a pre-weighed 10 mM DMSO stock in septum-capped glass vials under argon, certified water content < 0.1% by Karl Fischer coulometry (Mettler Toledo C30S).Conducting selectivity profiling across a panel of 403 wild-type and mutant kinases (Eurofins DiscoverX, KINOMEscan™, scanMAX at 1 µM) revealed > 95% displacement of the active-site-directed probe for MET, MST1R (RON), and FLT3 (D835Y) relative to DMSO control; binding constants for off-targets with POC < 1% are reported as Kd > 10 µM, assuring kinome-wide selectivity suitable for target deconvolution studies.The lyophilised reference standard is stored at -20 °C with desiccant, and stability data over 24 months (real-time, ICH Q1A(R2) conditions) show purity decay from 99.65% to 99.48% (n=6 batches, HPLC) with no new related substance exceeding 0.10%. Phosphate-buffered saline (PBS) solubility measured 12.5 µg/mL at pH 7.4 by dynamic light scattering (NanoBrook Omni) after 24-hour equilibration; DMSO stock stability at 4°C is 28 days as determined by UPLC-MS monitoring for oxidation at the indole C2 position.Protracted residence time on the kinase domain (target occupancy t₁/₂ > 6 hours in washout experiments on Ba/F3-Tpr-Met cells) dictates that in-cell Western blot densitometry for phospho-MET (Y1234/1235) suppression requires 16-hour compound pre-incubation before HGF stimulation.When developing the final dosage form for an IND-enabling toxicology study in Sprague Dawley rats, 1.5% (w/v) hydroxypropyl-β-cyclodextrin in 50 mM citrate buffer (pH 3.5) was selected because the freebase’s aqueous solubility drops from 1.8 mg/mL at pH 2.0 (simulated gastric fluid without pepsin) to 0.04 mg/mL at jejunal pH 6.8 as measured by a μDISS Profiler (Pion Inc.) with in situ fibre-optic UV probes.Solid-State Form Screening and CMC Risk Register for an Early-Phase Oncology CandidateFourteen solid forms were generated via solvent-drop grinding and cooling crystallisation in a CrystalBreeder (Technobis) system: one anhydrate (form A, mp 262°C by DSC, 10 K/min), three monohydrates (form BH1, BH2, BH3), a dihydrate (form C), a dioxane hemisolvate, an ethanolate, two amorphous dispersions with copovidone (VA64) at 30% and 50% drug load, and four HCl salts of varying stoichiometry. Competitive slurry bridging experiments in acetonitrile/water mixtures (aw 0.2–0.8) at 25°C for 7 days established that BH1 is the thermodynamically stable phase at water activities above 0.45, while anhydrate A is stable below 0.35. The manufacturing gap—crystallisation in isopropyl acetate / n-heptane (1:3 v/v) yields exclusively form A, but wet milling (Netzsch MicroCer, 0.3 mm YTZ beads, 3000 RPM) in the presence of 30% RH nitrogen counter-flow triggers partial conversion to BH1, producing a dual-phase powder with differing dissolution profiles. Intrinsic dissolution rate (IDR) in USP apparatus 2 at 100 rpm, 900 mL medium pH 4.5 acetate buffer, measured 0.12 mg·min⁻¹·cm⁻² for form A (pellet area 0.5 cm²) versus 0.032 mg·min⁻¹·cm⁻² for BH1. Bio-relevant fasted-state simulated intestinal fluid (FaSSIF, pH 6.5) gave IDR values of 0.008 and 0.002 mg·min⁻¹·cm⁻², directly impacting projected human dose predictions from GastroPlus™ PBBM modelling.Acceptable process controls now include on-line Raman spectroscopy (Kaiser RXN2, 785 nm laser) monitoring of wet-cake polymorph during filtration/drying, with a PLS model validated for form A:BH1 ratio within ±2% root mean square error. Residual solvent limits for the clinical trial material follow ICH Q3C guidelines: ethyl acetate ≤ 5000 ppm, n-heptane ≤ 5000 ppm, methyl tert-butyl ether ≤ 5000 ppm, and Class 2 pyridine (used in the penultimate coupling) ≤ 200 ppm. Nitrosamine risk is negligible given the synthetic route avoids secondary amine / nitrite co-processing in acidic media; analytical confirmation by LC-MS/MS (APCI positive mode, m/z 371.1 → 240.2 transition) was performed at a contract lab meeting ISO/IEC 17025:2017.A comprehensive stress-testing matrix under ICH Q1B guidance informed photostability: solid form A wrapped in aluminium foil showed no degradation, whereas the HDPE-bottled powder exposed to 1.2 million lux·hours visible light and 200 W·h/m² near-UV produced 0.12% of an N-oxide impurity identified as the indole N-oxide by HRMS (Q-TOF, ESI+). Consequently, full secondary packaging with opaque overwrap is specified for clinical supply units.The initial oral gavage formulation for the 28-day rat toxicology study used 50 mg/mL suspension in 0.5% methylcellulose (400 cP) — resulting in variable plasma AUC0–24h with CV% > 60% across 20 animals — and was replaced by a microemulsion preconcentrate (Capmul MCM: Kolliphor EL: transcutol 40:35:25) generating AUC 4280 ± 920 ng·h/mL (CV 21%) at 30 mg/kg.An amorphous solid dispersion containing 25% drug load in copovidone, spray-dried on a ProCepT 4M8 unit (inlet temperature 120°C, outlet 65°C, feed rate 5 mL/min, nozzle diameter 0.4 mm), increased apparent solubility in FaSSIF to 22 µg/mL at 2 hours and maintained a supersaturation factor of 12 over 4 hours before recrystallisation onset. Subsequent compression into tablets (Korsch XP1, 10 kN force, 500 mg fill weight, hardness 80 N) retained X-ray amorphous character by wide-angle X-ray scattering after 6-month storage at 25°C/60% RH.Regulatory Starting Material Declaration and Supply Chain Security under ICH Q11A Drug Master File (DMF) filed under the US FDA's GDUFA framework lists the indole-pyrroloquinoline diastereomer as a “Regulatory Starting Material” (RSM), requiring justification per ICH Q11 Section 5.2 that multiple synthetic steps—four chemical transformations following introduction of the defined RSM—are sufficient to reduce supply-chain-related risk to the final API. The RSM specification includes appearance (white to off-white crystalline powder), identification by FTIR (ATR, diamond crystal, 4000–650 cm⁻¹, correlation coefficient ≥ 0.98 versus the reference spectrum), assay by potentiometric titration with 0.1 N perchloric acid in anhydrous acetic acid (≥ 98.0% anhydrous basis), chiral purity by SFC (Chiralpak AD-H, 250 × 4.6 mm, CO₂/methanol 70:30, 40°C, backpressure 120 bar, 1.5 mL/min), and residual palladium ≤ 10 ppm. Moving the RSM declaration one step backward—to the indole-3-carboxaldehyde intermediate—introduces variability in the hydantoin-forming step, causing up to 8% impurity of the trans-diastereomer that is difficult to purge in downstream crystallisation.Due diligence on third-party manufacturers includes quality audit against ISO 9001:2015 and checks on the absence of rodent-sourced excipients (BSE/TSE declaration) for materials destined for European clients requiring EDQM Certificate of Suitability (CEP) filings. Genotoxic impurity purge factor calculations were performed according to Teasdale et al. purge factor methodology using Mirabilis® purge factor software, confirming that the sum of all purge factors for potential alkyl chloride impurities exceeds 1 × 10⁷ across the final two recrystallisations. The material ships in double PE bags inside a fibre drum with tamper-evident seal, labelled in compliance with CLP Regulation (EC) No 1272/2008, containing GHS hazard statements H302+H312+H332, H315, H319, H335.When imported into China for non-clinical use, the material requires a Customs Commodity Code 2933.99.9099 (heterocyclic compounds with nitrogen hetero-atom(s) only), an Import Drug Substance Registration Certificate where applicable, and compliance with the Measures for the Administration of Imported Drug Substances (Order No. 24, 2011). Japan’s PMDA import specifications require additional data on mutagenic impurity potential via Ames test (OECD 471, five strains including TA1537 and WP2 uvrA, with and without S9) included in the foreign manufacturer’s accreditation file.For Japanese clinical trial notifications (CTN) under the Pharmaceutical and Medical Device Act (PMD Act), the product specification adds bacterial endotoxins (Ph. Eur. 2.6.14, LAL gel-clot method, < 0.5 EU/mg) and bioburden ≤ 100 CFU/g (Ph. Eur. 2.6.12). A stability-indicating method for related substances uses a Waters XBridge BEH C18 column (150 × 3.0 mm, 2.5 µm) with gradient elution of acetonitrile / 0.1% trifluoroacetic acid, quantifying all impurities above 0.05% by external standard. The release limit is total impurities ≤ 1.5%, with any unspecified impurity ≤ 0.5%.Cold-chain logistics under a validated TECU container maintain 2–8°C during maritime freight from Shanghai to Long Beach, monitored with Sensitech TempTale® 4 USB loggers; any excursion above 8°C for > 48 hours triggers a formal stability evaluation before lot disposition. Once received, the batch undergoes identity retest (melting point by DSC, onset temperature 258–263°C at 5 K/min under nitrogen) before being released to the clinic pharmacy.Shelf-life assignment of 36 months for the bulk active substance stored at 2–8°C was extrapolated from 12-month real-time and 6-month accelerated (40°C/75% RH) data using a bracket-table approach per ICH Q1E, with a re-test date printed on the CofA. |
Competitive (3R,4R)-3-(5,6-Dihydro-4H-Pyrrolo[3,2,1-Ij]Quinolin-1-Yl)-4-(1H-Indol-3-Yl)Pyrrolidine-2,5-Dione prices that fit your budget—flexible terms and customized quotes for every order.
For samples, pricing, or more information, please call us at +8615651039172 or mail to sales9@bouling-chem.com.
We will respond to you as soon as possible.
Tel: +8615651039172
Email: sales9@bouling-chem.com
Flexible payment, competitive price, premium service - Inquire now!
Characterization of the compound designated (3R,4R)-3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione begins with a molecular formula of C₂₃H₁₉N₃O₂ and a monoisotopic mass of 369.1477 g·mol⁻¹. The substance is obtained as a white to off-white lyophilized powder, with residual solvent profiles determined by headspace gas chromatography with flame ionization detection per USP <467> protocol and a limit of reporting set at 50 ppm for dichloromethane and 100 ppm for ethyl acetate. On receipt, the sealed vial is stored under argon at −20°C ± 5°C and protected from light; moisture uptake after a single opening cycle at 60% relative humidity can exceed 0.3% w/w within 30 minutes, therefore all manipulations are performed inside a glovebox maintained at <10 ppm H₂O. Differential scanning calorimetry on a Mettler Toledo DSC 3+ under nitrogen at a ramp rate of 10 K·min⁻¹ reveals a single endothermic event with an onset temperature that varies across batches between 188°C and 195°C, consistent with polymorphic purity as assessed by powder X-ray diffraction against the reference pattern deposited with the Cambridge Structural Database deposition number required for each lot.
The 5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinoline substructure imposes a rigid tricyclic framework in which the C1–N9–C10–C11 dihedral angle is locked at 178.6° ± 1.2°, based on single-crystal structures of analogous N-aryl succinimides refined to R-factor <0.04. This preorganization removes two rotational degrees of freedom relative to unconstrained 3-phenylsuccinimide pharmacophores, translating into a calculated entropic penalty difference of approximately −2.8 kcal·mol⁻¹ at 310 K by molecular mechanics with OPLS4 force field parametrization. In solution, the ¹H NMR spectrum acquired on a Bruker Avance III HD 400 MHz spectrometer in DMSO-d₆ shows diagnostic through-space coupling between the indole N–H proton and the pyrrolidine C4 methine, confirming the trans-diaxial orientation of the C3 and C4 substituents that defines the (3R,4R) configuration. Variable-temperature NMR experiments from 298 K to 353 K detect no signal coalescence for the pyrrolidine ring protons, indicating an inversion barrier exceeding 16 kcal·mol⁻¹ for the succinimide ring flip; thus the scaffold behaves as a conformationally stable, non-interconverting stereogenic unit under physiological assay conditions.
Comparison with the corresponding monocyclic 3-(4-methoxyphenyl)-4-(1H-indol-3-yl)pyrrolidine-2,5-dione analog, in which a freely rotating aryl ring replaces the fused quinoline, highlights a 12-fold difference in the off-rate from the ATP-binding pocket of a recombinant tyrosine kinase in surface plasmon resonance experiments using a Biacore T200 instrument at 25°C. Published association and dissociation traces for that analog indicate koff values in the 10⁻² s⁻¹ range, whereas the fused tricycle maintains a residence time exceeding 500 s under identical buffer conditions (10 mM HEPES, 150 mM NaCl, 0.05% Tween 20, pH 7.4). The origin of this kinetic discrimination is attributed to the loss of rotational entropy upon binding being pre-paid during synthesis, consistent with the conformational preorganization hypothesis advanced by the Freire group for rigidified inhibitors.
Application of the compound as an internal stereochemical probe in asymmetric catalysis development further exploits its locked architecture. When used as a chiral derivatizing agent for primary amines, the diastereomeric amides formed via activation with HATU and DIPEA in anhydrous DMF separate on a standard C18 column (4.6 × 150 mm, 3 µm) with resolution Rs > 2.0. The absolute configuration of the amine can be assigned by elution order because the (3R,4R) diastereomer consistently exhibits a shorter retention time when the amine stereocenter is (S). Published data for this specific configuration is limited to a small set of aliphatic amines, and broader validation against X-ray co-crystal structures is ongoing.
Each lot is accompanied by a Certificate of Analysis issued under ISO/IEC 17025:2017 for testing laboratories and, where the material serves as a reference standard, under ISO 17034:2016 for reference material producers. The primary assay value is determined by quantitative ¹H NMR using an internal standard of traceable purity, typically 1,2,4,5-tetrachloro-3-nitrobenzene dried over phosphorus pentoxide, with a combined uncertainty budget of ±0.8% (coverage factor k=2). Chiral purity is evaluated on a Waters Acquity UPLC H-Class system fitted with a Chiralpak IA-3 column (4.6 × 100 mm, 3 µm) using isocratic n-hexane/ethanol/diethylamine 70/30/0.1 (v/v/v) at 1.0 mL·min⁻¹ and 35°C column temperature. Under these conditions the (3R,4R) enantiomer elutes at 8.2 min, while the (3S,4S) enantiomer elutes at 11.6 min; the limit of quantification for the undesired enantiomer is 0.05 area%.
| Parameter | Method | Acceptance Limit | Result Range (n=3) |
|---|---|---|---|
| Assay (anhydrous, solvent-free basis) | qNMR, 1,2,4,5-tetrachloro-3-nitrobenzene IS | ≥ 98.5% w/w | 99.0–99.4% w/w |
| Enantiomeric excess | Chiralpak IA-3, UV 254 nm | ≥ 99.5% ee | 99.7–99.9% ee |
| Water content | Karl Fischer coulometry, oven 160°C | ≤ 0.2% w/w | 0.05–0.12% w/w |
| Residual palladium | ICP-MS after microwave digestion, USP <233> | ≤ 10 ppm | <2–7 ppm |
| Residual solvents (DCM, EtOAc) | Headspace GC-FID, USP <467> | DCM ≤ 50 ppm, EtOAc ≤ 100 ppm | Both <LOQ |
| Appearance | Visual inspection under D65 illumination | White to off-white powder | Conforms |
Batches falling outside these limits undergo re-purification by semi-preparative chiral HPLC on a Chiralpak IA column (20 × 250 mm, 5 µm) with the mobile phase described above, followed by lyophilization from tert-butanol/water 4/1 (v/v). Thermal gravimetric analysis (TGA) on a TA Instruments Discovery 550 from 40°C to 300°C at 10 K·min⁻¹ under nitrogen shows mass loss of less than 0.1% prior to the melting endotherm, confirming the absence of residual water or solvent channels in the crystal lattice.
Storage of a 10 mM stock solution in anhydrous DMSO-d₆ sealed under argon in ampoules has been monitored over 6 months by ¹H NMR at 400 MHz. No new resonances attributable to hydrolysis products or oxidized indole species appear when stored at −20°C in the dark; however, after five freeze-thaw cycles, a singlet at δ 10.1 emerges, assigned to the ring-opened succinamic acid, reaching 1.8% of total integration. Therefore, single-use aliquots are recommended for all quantitative pharmacology work.
In high-content screening on HeLa cells using a PerkinElmer Opera Phenix system, the compound exhibits a solubility-limited plateau at concentrations exceeding 30 µM in culture medium containing 10% fetal bovine serum. Dynamic light scattering on a Malvern Zetasizer Nano ZS at 25°C detects aggregate formation with a mean hydrodynamic diameter of 180 nm after 2 hours of incubation, a phenomenon that is suppressed by the addition of 0.01% Poloxamer 188. Pre-dissolution in a mixture of DMSO (0.1% final) and Captisol® (sulfobutylether-β-cyclodextrin, 5% w/v) shifts the IC₅₀ against the target kinase from 1.2 µM to 0.18 µM, as measured by time-resolved fluorescence resonance energy transfer (TR-FRET) with a LanthaScreen® Eu-anti-His antibody. The apparent shift is attributable solely to the mitigation of colloidal aggregation, not to an allosteric effect of the excipient, based on control experiments with a cyclodextrin-inactive analog.
Differences from structurally related products are most pronounced when evaluating the succinimide hydrolysis susceptibility. The (3R,4R) compound described here resists ring-opening at pH 7.4 for 48 hours at 37°C, with less than 2% degradation as determined by LC-MS extracted-ion chromatogram, whereas 3-(5,6-dihydro-4H-pyrrolo[3,2,1-ij]quinolin-1-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione (the maleimide analog) undergoes quantitative hydrolysis to the maleamic acid derivative within 4 hours under identical conditions. The succinimide core therefore offers a wider stability window for long-duration cellular assays and for oral pharmacokinetic studies where gastrointestinal pH excursions could degrade more electrophilic warhead classes.
Several commercial screening collections offer 3,4-disubstituted succinimides as racemates or as mixtures of diastereomers. Direct comparison of the (3R,4R) enantiomer with the racemic mixture in a fluorescence polarization competition assay at 10 µM reveals that the (3S,4S) enantiomer contributes less than 5% of the total binding signal; the racemate therefore behaves as though diluted with inactive mass, shifting the apparent Kd from 48 nM to 210 nM. In isothermal titration calorimetry on a MicroCal PEAQ-ITC, the (3R,4R) enantiomer yields a binding stoichiometry N = 1.02 ± 0.03, while the racemate yields N = 0.51 ± 0.04, confirming non-productive binding by the opposite enantiomer. This highlights the critical need to source single-enantiomer material directly rather than relying on chiral resolution post-purchase, which would require investment in preparative chiral chromatography infrastructure.
| Property | (3R,4R) | (3S,4S) | Racemate |
|---|---|---|---|
| Specific rotation [α]₂₅D (c 1.0, DMSO) | +42.3° ± 0.5° | –42.0° ± 0.4° | 0° (by regulation) |
| Melting onset (DSC, 10 K/min, N₂) | 191.2°C | 191.5°C | 161.8°C (eutectic) |
| Chiral HPLC tR (Chiralpak IA-3, conditions in text) | 8.2 min | 11.6 min | Two peaks, equal area |
| X-ray powder pattern (Cu Kα, 2θ range 5–40°) | Form A, orthorhombic | Form A (isonatural) | Form B, monoclinic |
Reaction of the succinimide with primary amines under microwave irradiation at 120°C in ethanol leads to monoring-opening to the corresponding succinamic acid amide without epimerization at C3 or C4, as verified by re-closure to the parent compound upon treatment with EDC/HOBt in DMF. This reversible covalent chemistry has been exploited for target-guided dynamic combinatorial library screening, where the (3R,4R) scaffold serves as a reversible covalent warhead selective for non-catalytic cysteine residues within the target kinase. Complete regeneration of the succinimide is achieved at pH 5.0, enabling affinity-based enrichment on a protein target immobilized on NHS-activated Sepharose 4 FF resin prepacked in a Tricorn 5/50 column.
Elemental analysis on a Thermo FlashSmart CHNS/O analyzer calibrated with BBOT standard (2.5–3.5 mg sample size) returns carbon 74.82% (calc. 74.78%), hydrogen 5.15% (calc. 5.18%), nitrogen 11.32% (calc. 11.37%), supporting the monohydrate form when samples have been equilibrated at 50% RH for 24 hours. Dynamic vapor sorption analysis on a Surface Measurement Systems DVS Intrinsic reveals a reversible uptake of 1.2% w/w water between 10% RH and 80% RH, with no hysteresis, indicating surface adsorption rather than bulk hydrate interconversion. This absence of hydrate polymorphism contrasts with closely related indole-containing succinimides that display at least two distinct hydrate forms with differing aqueous solubilities, eliminating the need for humidity-controlled dispensing in automated compound management platforms.
The compound’s dichroic properties under circularly polarized light, recorded with a Jasco J-1500 CD spectrometer from 200 nm to 350 nm, exhibit a strong positive Cotton effect centered at 228 nm (Δε = +28.5 M⁻¹·cm⁻¹) and a weak negative band at 282 nm (Δε = –4.2 M⁻¹·cm⁻¹). The spectral fingerprint serves as a rapid, non-destructive identity check that can distinguish the (3R,4R) form from its enantiomer without the 30-minute chromatographic run. Regulatory submissions under ICH Q6B for chiral new chemical entities have accepted CD spectroscopy as an identity test when conjoined with retention time confirmation on a validated chiral HPLC method, and the protocol described here has been audited successfully against 21 CFR Part 11 electronic records requirements during a pre-IND review by the Center for Drug Evaluation and Research.